Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

Koch J, Tesar M.

Transfus Med Hemother. 2017 Sep;44(5):337-350. doi: 10.1159/000479981. Epub 2017 Sep 11. Review.

2.

Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.

Cho C, Hsu M, Barba P, Maloy MA, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Jakubowski AA, Koehne G, Meagher RC, O'Reilly RJ, Papadopoulos EB, Ponce DM, Tamari R, van den Brink MRM, Young JW, Devlin SM, Perales MA.

Bone Marrow Transplant. 2017 Dec;52(12):1629-1636. doi: 10.1038/bmt.2017.197. Epub 2017 Oct 9.

PMID:
28991247
3.

Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34+ Selected Hematopoietic Cell Transplantation.

Huang YT, Kim SJ, Lee YJ, Burack D, Nichols P, Maloy M, Perales MA, Giralt SA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1759-1766. doi: 10.1016/j.bbmt.2017.06.008. Epub 2017 Jun 28.

PMID:
28668490
4.

Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease.

Dudakov JA, Mertelsmann AM, O'Connor MH, Jenq RR, Velardi E, Young LF, Smith OM, Boyd RL, van den Brink MRM, Hanash AM.

Blood. 2017 Aug 17;130(7):933-942. doi: 10.1182/blood-2017-01-762658. Epub 2017 Jun 12.

PMID:
28607133
5.

FLT3 ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche.

Williams KM, Moore AR, Lucas PJ, Wang J, Bare CV, Gress RE.

Exp Hematol. 2017 Aug;52:40-49. doi: 10.1016/j.exphem.2017.05.005. Epub 2017 May 26.

PMID:
28552733
6.

Administration of RANKL boosts thymic regeneration upon bone marrow transplantation.

Lopes N, Vachon H, Marie J, Irla M.

EMBO Mol Med. 2017 Jun;9(6):835-851. doi: 10.15252/emmm.201607176.

7.

Treatment of Pediatric Acute Graft-versus-Host Disease-Lessons from Primary Immunodeficiency?

Flinn AM, Gennery AR.

Front Immunol. 2017 Mar 21;8:328. doi: 10.3389/fimmu.2017.00328. eCollection 2017. Review.

8.

Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, Perales MA.

Leuk Lymphoma. 2017 Aug;58(8):1859-1871. doi: 10.1080/10428194.2016.1265113. Epub 2017 Jan 10.

PMID:
28073320
9.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, El Kassar N, Le RQ, Schultz KR, Griffith LM, Savani BN, Wingard JR.

Biol Blood Marrow Transplant. 2017 Jun;23(6):870-881. doi: 10.1016/j.bbmt.2016.10.001. Epub 2016 Oct 14. Review.

PMID:
27751936
10.

Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors.

Mussetti A, Kernan NA, Prockop SE, Scaradavou A, Lehrman R, Ruggiero JM, Curran K, Kobos R, O'Reilly R, Boulad F.

Pediatr Hematol Oncol. 2016 Sep;33(6):347-358. Epub 2016 Oct 7.

11.

Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation.

Drylewicz J, Schellens IM, Gaiser R, Nanlohy NM, Quakkelaar ED, Otten H, van Dorp S, Jacobi R, Ran L, Spijkers S, Koning D, Schuurman R, Meijer E, Pietersma FL, Kuball J, van Baarle D.

J Transl Med. 2016 Aug 2;14(1):230. doi: 10.1186/s12967-016-0988-4.

12.

Modeling Human Leukemia Immunotherapy in Humanized Mice.

Xia J, Hu Z, Yoshihara S, Li Y, Jin CH, Tan S, Li W, Chen Q, Sykes M, Yang YG.

EBioMedicine. 2016 Aug;10:101-8. doi: 10.1016/j.ebiom.2016.06.028. Epub 2016 Jun 23.

13.

Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.

Mehta RS, Rezvani K.

Virulence. 2016 Nov 16;7(8):901-916. Epub 2016 Jul 6. Review.

14.

Intensive care outcomes in adult hematopoietic stem cell transplantation patients.

Bayraktar UD, Nates JL.

World J Clin Oncol. 2016 Feb 10;7(1):98-105. doi: 10.5306/wjco.v7.i1.98. Review.

15.

Cord Blood as a Source of Natural Killer Cells.

Mehta RS, Shpall EJ, Rezvani K.

Front Med (Lausanne). 2016 Jan 5;2:93. doi: 10.3389/fmed.2015.00093. eCollection 2015. Review.

16.

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients.

Hobbs GS, Perales MA.

J Clin Med. 2015 Mar 19;4(3):488-503. doi: 10.3390/jcm4030488. Review.

17.

Models to Study NK Cell Biology and Possible Clinical Application.

Zamora AE, Grossenbacher SK, Aguilar EG, Murphy WJ.

Curr Protoc Immunol. 2015 Aug 3;110:14.37.1-14. doi: 10.1002/0471142735.im1437s110. Review.

18.

A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency.

Hsieh J, Ng S, Bosinger S, Wu JH, Tharp GK, Garcia A, Hossain MS, Yuan S, Waller EK, Galipeau J.

Clin Transl Immunology. 2015 May 8;4(5):e37. doi: 10.1038/cti.2015.8. eCollection 2015 May.

19.

Sex steroid ablation: an immunoregenerative strategy for immunocompromised patients.

Velardi E, Dudakov JA, van den Brink MR.

Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S77-81. doi: 10.1038/bmt.2015.101. Review.

20.

General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation.

Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1284-90. doi: 10.1016/j.bbmt.2015.02.017. Epub 2015 Feb 20.

Supplemental Content

Support Center